NCT03611738 2026-02-09Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLCH. Lee Moffitt Cancer Center and Research InstitutePhase 1 Active not recruiting21 enrolled
NCT02299505 2022-02-09Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)NovartisPhase 1 Completed306 enrolled